Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LY364947
- Development stage
- Preclinical
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Intraperitoneal (in Animal Models), Not For Clinical Human Use
01
Overview
LY364947 is a **selective small-molecule inhibitor** of the **transforming growth factor-beta type I receptor** (TGF-βRI, also known as ALK-5), acting as an ATP-competitive kinase inhibitor. It is used primarily as a research tool for dissecting TGF-β/SMAD signaling and has demonstrated efficacy in blocking phospho-SMAD2 and SMAD3 mediated signaling. LY364947 inhibits TGF-β–dependent cellular responses such as epithelial-mesenchymal transition (EMT), cell motility, and tumor invasion or progression in diverse preclinical cancer models, and has been studied in vitro and in vivo in the context of cancer and fibrosis. Its molecular formula is C17H12N4, with a molecular weight of 272.3, and the CAS number is 396129-53-6[1][3][5][6][7][9].
- Other names
- TbetaR-I InhibitorTransforming Growth Factor-beta Type I Receptor Kinase Inhibitor
02
Targets
PK (Pyruvate kinase)TGFBR1RK (Ribokinase)TGFBR2 (TGF-β receptor type 2)
Beyond the preview
Go deeper on LY364947.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LY364947.